IGM Biosciences (IGMS) Stock Price, News & Analysis

Company Overview

IGM Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel immunotherapies based on engineered immunoglobulin M (IgM) antibodies. Utilizing a proprietary IgM platform, the company aims to harness the high avidity and potent complement activation properties of pentameric IgM molecules to address a range of oncology and infectious disease targets. By leveraging this unique antibody format, IGM Biosciences seeks to overcome limitations of conventional IgG therapeutics and deliver improved binding strength and efficacy.

The company’s lead oncology candidates include IGM‐2323, an anti‐CD20 IgM antibody in Phase 1/2 development for relapsed or refractory non‐Hodgkin lymphoma, and IGM‐8444, an anti‐death receptor 5 (DR5) IgM molecule targeting solid tumors. Both programs are designed to induce tumor cell lysis through enhanced complement-dependent cytotoxicity and immune effector engagement. In addition to its oncology pipeline, IGM Biosciences is advancing early‐stage programs in infectious diseases and autoimmunity, illustrating the versatility of its IgM platform across multiple therapeutic areas.

Founded in 2014 and headquartered in Carlsbad, California, IGM Biosciences went public on the NASDAQ in June 2020. The company conducts its research, development, and early clinical studies primarily in the United States, while collaborating with academic and industry partners to support global trial initiatives. IGM Biosciences maintains research facilities in California and has established strategic alliances to expand its scientific capabilities and accelerate its pipeline.

Under the leadership of President and Chief Executive Officer Andrew Adams, IGM Biosciences has grown its multidisciplinary team of antibody engineers, clinical development experts, and regulatory specialists. The company continues to advance its novel IgM therapeutics with the goal of delivering first‐in‐class treatments for patients with high unmet medical needs in oncology and beyond.

Key Stats

• Today's Range: $1.27 to $1.27
• 50-Day Range: $1.26 to $1.36
• 52-Week Range: $1.08 to $1.47
• Volume: N/A
• Average Volume: 535,598 shs
• Market Capitalization: $76.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 7/31/2025
• Today: 6/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IGMS
• CIK: 1496323
• Web: igmbio.com
• Phone: 650-965-7873
• Fax: N/A
• Employees: 190
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$195.79 million
• Net Margins: -36.81%
• Pretax Margin: -36.81%
• Return on Equity: -93.35%
• Return on Assets: -24.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.66
• Quick Ratio: 17.66

Sales & Book Value

• Annual Sales: $145.05 million
• Price / Sales: 0.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 60,293,000
• Free Float: 25,926,000
• Market Cap: $76.57 million
• Optionable: Optionable
• Beta: 0.60